Milestone Pharmaceuticals

OverviewSuggest Edit

Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of paroxysmal supraventricular tachycardia (PSVT).

The Company employs a lean and cost efficient model which has the effect of minimizing overhead and focusing spending on the programs. It has assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors.

TypePublic
Founded2005
HQMontréal, CA
Websitemilestonepharma.com

Latest Updates

Employees (est.) (Dec 2019)30
Share Price (Feb 2021)$7.2 (-2%)
Cybersecurity ratingAMore

Key People/Management at Milestone Pharmaceuticals

Joseph Oliveto

Joseph Oliveto

President & CEO
Philippe Douville

Philippe Douville

Founder and Strategic Advisor
Robert J. Wills

Robert J. Wills

Chairman of the Board
Francis Plat

Francis Plat

Chief Medical Officer
Lisa M. Giles

Lisa M. Giles

Independent Non-Executive Director
Lorenz Muller

Lorenz Muller

Chief Commercial Officer
Show more

Milestone Pharmaceuticals Office Locations

Milestone Pharmaceuticals has offices in Montréal and Charlotte
Montréal, CA (HQ)
420 1111 Boulevard Dr.-Frederik-Philips
Charlotte, NC, US
7422 Carmel Executive Park Dr #300
Show all (2)

Milestone Pharmaceuticals Financials and Metrics

Milestone Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(13.0m)

EBIT (Q2, 2020)

(13.1m)

Market capitalization (26-Feb-2021)

209.2m

Closing stock price (26-Feb-2021)

7.2

Cash (30-Jun-2020)

53.4m

EV

156.0m
Milestone Pharmaceuticals's current market capitalization is $209.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

1.5m3.1m7.0m

R&D expense

5.6m16.8m42.0m

Operating expense total

8.3m23.8m49.0m

EBIT

(8.3m)(23.8m)(57.9m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

979.0k1.6m2.1m2.7m3.0m

R&D expense

7.8m10.5m9.5m11.9m8.6m

Operating expense total

8.7m12.2m11.6m14.6m11.6m

EBIT

(10.9m)(14.3m)(13.7m)(16.8m)(13.1m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

10.9m85.9m119.8m

Accounts Receivable

258.0k

Prepaid Expenses

100.0k1.4m1.8m

Current Assets

27.6m88.1m122.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

71.2m110.8m106.5m101.8m53.4m

Accounts Receivable

265.0k338.0k497.0k259.0k318.0k

Prepaid Expenses

5.5m5.0m3.5m1.6m6.1m

Current Assets

77.3m151.6m141.0m104.3m92.4m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(8.1m)(23.2m)(55.2m)

Depreciation and Amortization

8.0k10.0k38.0k

Accounts Payable

(222.0k)2.9m3.5m

Cash From Operating Activities

(8.1m)(21.0m)(51.2m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(10.5m)(24.1m)(36.9m)(16.3m)(29.3m)

Depreciation and Amortization

3.0k5.0k14.0k24.0k49.0k

Accounts Payable

(571.0k)1.1m4.0m(2.8m)(3.2m)

Cash From Operating Activities

(14.7m)(26.3m)(34.5m)(18.1m)(34.6m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Milestone Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Milestone Pharmaceuticals Online and Social Media Presence

Embed Graph

Milestone Pharmaceuticals News and Updates

Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT

– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 – MONTREAL...

Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended...

Thinking about buying stock in Milestone Pharmaceuticals, Advanced Micro Devices, CymaBay Therapeutics, Pfizer Inc, or AT&T?

NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MIST, AMD, CBAY, PFE, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm

SAN DIEGO, March 23, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Milestone Pharmaceuticals Inc. (NASDAQ: MIST) ("Milestone or the "Company") for violations of federal securities laws. On or about May 9, 2019, Milestone...

Milestone Pharmaceuticals to Participate in Upcoming Investor Conferences

MONTREAL and CHARLOTTE, N.C., Aug. 29, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. today announced that members of the Milestone management team will participate in the following September investor conferences: Citi's 14th Annual Biotech Conference on Thursday, September 5, 2019...

Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting

MONTREAL and CHARLOTTE, N.C., May 21, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the...
Show more

Milestone Pharmaceuticals Blogs

Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference Content Import Wed, 11/11/2020 - 07:01 Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference November 11, 2020 This release is a ba…

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants Content Import Thu, 10/22/2020 - 16:02 Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants October 22, 2020 …

Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc.  (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its

Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update Content Import Wed, 08/12/2020 - 07:01 Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update August…

Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference Content Import Thu, 08/06/2020 - 07:02 Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference August 06, 2020 This release is a ba…

Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

MONTREAL and CHARLOTTE, N.C. , May 27, 2020 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive
Show more

Milestone Pharmaceuticals Frequently Asked Questions

  • When was Milestone Pharmaceuticals founded?

    Milestone Pharmaceuticals was founded in 2005.

  • Who are Milestone Pharmaceuticals key executives?

    Milestone Pharmaceuticals's key executives are Joseph Oliveto, Philippe Douville and Robert J. Wills.

  • How many employees does Milestone Pharmaceuticals have?

    Milestone Pharmaceuticals has 30 employees.

  • Who are Milestone Pharmaceuticals competitors?

    Competitors of Milestone Pharmaceuticals include Biogen, Inovio Pharmaceuticals and MyoKardia.

  • Where is Milestone Pharmaceuticals headquarters?

    Milestone Pharmaceuticals headquarters is located at 420 1111 Boulevard Dr.-Frederik-Philips, Montréal.

  • Where are Milestone Pharmaceuticals offices?

    Milestone Pharmaceuticals has offices in Montréal and Charlotte.

  • How many offices does Milestone Pharmaceuticals have?

    Milestone Pharmaceuticals has 2 offices.